Clinical trials: Prostatic Cancer, Castration-Resistant
Prostate Cancer
Lenalidomide and Paclitaxel in Prostate Cancer
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of Revlimid® (lenalidomide) that can be given in combination with paclitaxel to patients with prostate cancer who have failed…
- Trial name
- NCT00933426
- Testing
- Lenalidomide, Paclitaxel
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well cabazitaxel and prednisone work in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body.
- Trial name
- NCT02844582
- Testing
- Cabazitaxel, Prednisone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, Davis
Metastatic Castration-Resistant Prostate Cancer
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
- Trial name
- ENZA-p (NCT04419402)
- Testing
- Lu-PSMA, Enzalutamide
- Where
- 15 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03805594
- Testing
- Lutetium Lu 177-PSMA-617, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer
This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration…
- Trial name
- LumOnate (NCT07090369)
- Testing
- Olaparib (300 mg BID), Pembrolizumab, 177Lu-PSMA-I&T
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Castration Resistant Prostate Cancer
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT03641560
- Testing
- Enzalutamide, Androgen deprivation therapy (ADT)
- Where
- 8 sites in India
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
Objectives: Primary: To evaluate the association of the probability of increase in phosphorylation of platelet-derived growth factor receptor (PDGFR) of > 0.5 in peripheral blood leucocytes following pre-operative docetaxel…
- Trial name
- NCT00811031
- Testing
- Taxotere, Prednisone
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
This is a phase 1b/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and pharmacokinetics /pharmacodynamics of AsiDNA in combination with olaparib in participants with recurrent…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
- Trial name
- NCT05700669
- Testing
- AsiDNA, Olaparib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Valerio Therapeutics
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05828082
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Cancer
Study of AZD0754 in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
- Trial name
- APOLLO (NCT06267729)
- Testing
- AZD0754, AZD2287
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Metastatic Prostate Cancer, Recurrent Prostate Cancer
Impact of Atorvastatin on Prostate Cancer Progression During ADT
This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- ESTO2 (NCT04026230)
- Testing
- Atorvastatin 80mg
- Where
- 10 sites in Denmark, Estonia and 2 more
- Volunteers
- 400 people
- Sponsor
- Tampere University Hospital
Prostate Cancer Metastatic
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in…
- Trial name
- TAXYNERGY (NCT01718353)
- Testing
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Where
- 19 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Sanofi
Prostate Cancer
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
The purpose of this study is to determine the safety and optimal dosing of intravenous copper chloride and disulfiram in men with metastatic castrate-resistant prostate cancer (CRPC).
- Trial name
- NCT02963051
- Testing
- Copper, Disulfiram, Copper gluconate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Daniel George, MD
Prostatic Neoplasms
Treatment Satisfaction With Ra-223 in Japan
This study aims to answer the research question: Are Japanese bone metastatic CRPC patients satisfied with their Ra-223 treatment, and what factors drive such satisfaction? It also aims to determine patient anxiety regarding…
- Trial name
- NCT03315260
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Japan
- Volunteers
- 85 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate…
- Trial name
- NCT06136650
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 330 sites in United States, Australia and 37 more
- Volunteers
- 1,314 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostatic Neoplasms
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants…
- Trial name
- NCT04108208
- Testing
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Where
- 27 sites in China
- Volunteers
- 75 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumor
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in…
- Trial name
- NCT06421935
- Testing
- M9466, Tuvusertib, Abiraterone acetate
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Castration-resistant Prostate Cancer
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once…
- Trial name
- NCT01972217
- Testing
- Olaparib, Abiraterone, Prednisone or prednisolone
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.